LSALT peptide: meta-analysis of COVID-19 studies

All studies   Mortality   Hospitalization   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -407% 1 61 Improvement, Studies, Patients Relative Risk Mortality -407% 1 61 Hospitalization -7% 1 61 RCTs -407% 1 61 Late -407% 1 61 LSALT peptide for COVID-19 c19early.org December 2025 FavorsLSALT peptide Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Somayaji (DB RCT) -407% 5.07 [0.25-101] death 2/30 0/31 Improvement, RR [CI] Treatment Control CATCO Fowler (RCT) unknown, >1.5 years late 580 (est. total) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.29 Late treatment -407% 5.07 [0.25-101] 2/30 0/31 407% higher risk All studies -407% 5.07 [0.25-101] 2/30 0/31 407% higher risk 1 LSALT peptide COVID-19 study (+1 unreported RCT) c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.29 Effect extraction pre-specified(most serious outcome) Favors LSALT peptide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Somayaji (DB RCT) -407% 5.07 [0.25-101] 2/30 0/31 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.29 Late treatment -407% 5.07 [0.25-101] 2/30 0/31 407% higher risk All studies -407% 5.07 [0.25-101] 2/30 0/31 407% higher risk 1 LSALT peptide COVID-19 mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.29 Favors LSALT peptide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Somayaji (DB RCT) -7% 1.07 [0.80-1.43] hosp. time 30 (n) 31 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Late treatment -7% 1.07 [0.80-1.43] 30 (n) 31 (n) 7% higher risk All studies -7% 1.07 [0.80-1.43] 30 (n) 31 (n) 7% higher risk 1 LSALT peptide COVID-19 hospitalization result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.65 Favors LSALT peptide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Somayaji (DB RCT) -407% 5.07 [0.25-101] death 2/30 0/31 Improvement, RR [CI] Treatment Control CATCO Fowler (RCT) unknown, >1.5 years late 580 (est. total) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.29 Late treatment -407% 5.07 [0.25-101] 2/30 0/31 407% higher risk All studies -407% 5.07 [0.25-101] 2/30 0/31 407% higher risk 1 LSALT peptide COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.29 Effect extraction pre-specified(most serious outcome) Favors LSALT peptide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Somayaji (DB RCT) -407% 5.07 [0.25-101] 2/30 0/31 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.29 Late treatment -407% 5.07 [0.25-101] 2/30 0/31 407% higher risk All studies -407% 5.07 [0.25-101] 2/30 0/31 407% higher risk 1 LSALT peptide COVID-19 RCT mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.29 Favors LSALT peptide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Somayaji (DB RCT) -407% 5.07 [0.25-101] death 2/30 0/31 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.29 Late treatment -407% 5.07 [0.25-101] 2/30 0/31 407% higher risk All studies -407% 5.07 [0.25-101] 2/30 0/31 407% higher risk 1 LSALT peptide COVID-19 peer reviewed studies c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.29 Effect extraction pre-specified(most serious outcome) Favors LSALT peptide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Somayaji (DB RCT) -407% 5.07 [0.25-101] death 2/30 0/31 Improvement, RR [CI] Treatment Control Somayaji (DB RCT) -203% 3.03 [0.13-71.7] death 1/30 0/31 Somayaji (DB RCT) -3% 1.03 [0.16-6.87] ARDS 2/30 2/31 Somayaji (DB RCT) -7% 1.07 [0.80-1.43] hosp. time 30 (n) 31 (n) LSALT peptide COVID-19 outcomes c19early.org December 2025 Favors LSALT peptide Favors control